Malte Kohns Vasconcelos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Malte Kohns Vasconcelos has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
Hanna Renk
Department of Paediatric Cardiology, Pulmonology and Intensive Care Medicine, University Children’s Hospital Tübingen, Tübingen, Germany
4 shared publications- Julia Anna Bielicki
Paediatric Research Centre, University Children’s Hospital Basel, Basel Switzerland and
4 shared publications - Hanna Renk
University Children’s Hospital Tuebingen, Tuebingen, Germany
3 shared publications - Alexandra Scherrer
Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
2 shared publications - Carlo Giaquinto
University of Padova
2 shared publications - Christian Raphael Kahlert
Division of Infectious Diseases, Kantonsspital St Gallen, St. Gallen, Switzerland
2 shared publications
Latest Publications
- 21 February 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (4) , e120-e121
Pediatric Perspective on the EUCAST Definitions for S, I and R
- 21 February 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (4) , e120-e121
Pediatric Perspective on the EUCAST Definitions for S, I and R
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , RCT5393
RCT Abstract - Effect of adjunct betamethasone vs placebo on time to clinical stabilisation upon hospital admission and risk of rehospitalisation in children with community-acquired pneumonia
Background: Adjunct steroids reduce mortality and may accelerate clinical stabilisation in adults with community-acquired pneumonia (CAP). Evidence in children is lacking. Objectives: To investigate whether adjunct oral corticosteroids in children hospitalised with CAP result in faster stabilisation (Co-primary effectiveness endpoint) while not being worse in terms of CAP-related readmission (Co-primary safety endpoint). Methods: This multicentre RCT enrolled children <14 years of age with clinical CAP at admission to 9 CH and 4 DE sites. Children were randomised to 2 days of oral betamethasone or placebo. Time to clinical stabilisation and CAP-related readmission were assessed through to week 4 (for safety: non-inferiority margin 7%; daily follow-up in hospital and at 1, 2 and 4 weeks by telephone). Results: We enrolled 510 children (Sep 2018 to Feb 2024), with 1 patient lost to follow-up. The median age was 34 months [IQR 19, 56]. 249 children were allocated to betamethasone and 260 to placebo. Patient characteristics were balanced between the trial arms. Median time to clinical stabilisation was 45.7 hours [95%CI 43.0, 57.8] in the betamethasone and 40.8 hours [95%CI 37.9, 45.0] in the placebo arm (logrank p = 0.671). With 18 and 14 CAP-related re-hospitalisations in the betamethasone and placebo arms, respectively, the risk difference was estimated at 1.8% [95% -2.8, 6.5]. Conclusion: While adjunct oral corticosteroids were non-inferior regarding CAP-related readmission, we did not observe faster clinical stabilisation. These results do not support the use of adjunct steroids in paediatric inpatient CAP.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , RCT5393
RCT Abstract - Effect of adjunct betamethasone vs placebo on time to clinical stabilisation upon hospital admission and risk of rehospitalisation in children with community-acquired pneumonia
Background: Adjunct steroids reduce mortality and may accelerate clinical stabilisation in adults with community-acquired pneumonia (CAP). Evidence in children is lacking. Objectives: To investigate whether adjunct oral corticosteroids in children hospitalised with CAP result in faster stabilisation (Co-primary effectiveness endpoint) while not being worse in terms of CAP-related readmission (Co-primary safety endpoint). Methods: This multicentre RCT enrolled children <14 years of age with clinical CAP at admission to 9 CH and 4 DE sites. Children were randomised to 2 days of oral betamethasone or placebo. Time to clinical stabilisation and CAP-related readmission were assessed through to week 4 (for safety: non-inferiority margin 7%; daily follow-up in hospital and at 1, 2 and 4 weeks by telephone). Results: We enrolled 510 children (Sep 2018 to Feb 2024), with 1 patient lost to follow-up. The median age was 34 months [IQR 19, 56]. 249 children were allocated to betamethasone and 260 to placebo. Patient characteristics were balanced between the trial arms. Median time to clinical stabilisation was 45.7 hours [95%CI 43.0, 57.8] in the betamethasone and 40.8 hours [95%CI 37.9, 45.0] in the placebo arm (logrank p = 0.671). With 18 and 14 CAP-related re-hospitalisations in the betamethasone and placebo arms, respectively, the risk difference was estimated at 1.8% [95% -2.8, 6.5]. Conclusion: While adjunct oral corticosteroids were non-inferior regarding CAP-related readmission, we did not observe faster clinical stabilisation. These results do not support the use of adjunct steroids in paediatric inpatient CAP.
- 31 March 2023
- Published by Swiss Society of Paediatrics in Paediatrica
- Vol. 34 (1)
Traitement antibiotique rationnel en pratique pédiatrique
Les antibiotiques figurent parmi les médicaments les plus utilisés en pédiatrie. Dans un contexte de résistances bactériennes croissantes contre les antibiotiques au courant de la dernière décennie, l’utilisation scrupuleuse et rationnelle de ces médicaments est apparue comme étant essentielle afin de conserver leur efficacité globalement le plus longtemps possible.
- 31 March 2023
- Published by Swiss Society of Paediatrics in Paediatrica
- Vol. 34 (1)
Traitement antibiotique rationnel en pratique pédiatrique
Les antibiotiques figurent parmi les médicaments les plus utilisés en pédiatrie. Dans un contexte de résistances bactériennes croissantes contre les antibiotiques au courant de la dernière décennie, l’utilisation scrupuleuse et rationnelle de ces médicaments est apparue comme étant essentielle afin de conserver leur efficacité globalement le plus longtemps possible.
- 31 March 2023
- Published by Swiss Society of Paediatrics in Paediatrica Stoffwechsel/rare disease
- Vol. 34 (1)
Rationale Antibiotikatherapie in der pädiatrischen Praxis
Antibiotika gehören zu den in der Kinder- und Jugendmedizin am häufigsten eingesetzten Medikamenten. Im Kontext steigender bakterieller Resistenzen gegen Antibiotika wurde im letzten Jahrzehnt vermehrt der bedachte und rationale Einsatz von Antibiotika als essentiell identifiziert, um die Wirksamkeit dieser Medikamente global möglichst lange zu erhalten.
- 31 March 2023
- Published by Swiss Society of Paediatrics in Paediatrica Stoffwechsel/rare disease
- Vol. 34 (1)
Rationale Antibiotikatherapie in der pädiatrischen Praxis
Antibiotika gehören zu den in der Kinder- und Jugendmedizin am häufigsten eingesetzten Medikamenten. Im Kontext steigender bakterieller Resistenzen gegen Antibiotika wurde im letzten Jahrzehnt vermehrt der bedachte und rationale Einsatz von Antibiotika als essentiell identifiziert, um die Wirksamkeit dieser Medikamente global möglichst lange zu erhalten.
- Open Access
- 1 January 2023
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 7 (1) , e44567
Migrating a Well-Established Longitudinal Cohort Database From Oracle SQL to Research Electronic Data Entry (REDCap): Data Management Research and Design Study
Background: Providing user-friendly electronic data collection tools for large multicenter studies is key for obtaining high-quality research data. Research Electronic Data Capture (REDCap) is a software solution developed for setting up research databases with integrated graphical user interfaces for electronic data entry. The Swiss Mother and Child HIV Cohort Study (MoCHiV) is a longitudinal cohort study with around 2 million data entries dating back to the early 1980s. Until 2022, data collection in MoCHiV was paper-based. Objective: The objective of this study was to provide a user-friendly graphical interface for electronic data entry for physicians and study nurses reporting MoCHiV data. Methods: MoCHiV collects information on obstetric events among women living with HIV and children born to mothers living with HIV. Until 2022, MoCHiV data were stored in an Oracle SQL relational database. In this project, R and REDCap were used to develop an electronic data entry platform for MoCHiV with migration of already collected data. Results: The key steps for providing an electronic data entry option for MoCHiV were (1) design, (2) data cleaning and formatting, (3) migration and compliance, and (4) add-on features. In the first step, the database structure was defined in REDCap, including the specification of primary and foreign keys, definition of study variables, and the hierarchy of questions (termed "branching logic"). In the second step, data stored in Oracle were cleaned and formatted to adhere to the defined database structure. Systematic data checks ensured compliance to all branching logic and levels of categorical variables. REDCap-specific variables and numbering of repeated events for enabling a relational data structure in REDCap were generated using R. In the third step, data were imported to REDCap and then systematically compared to the original data. In the last step, add-on features, such as data access groups, redirections, and summary reports, were integrated to facilitate data entry in the multicenter MoCHiV study. Conclusions: By combining different software tools-Oracle SQL, R, and REDCap-and building a systematic pipeline for data cleaning, formatting, and comparing, we were able to migrate a multicenter longitudinal cohort study from Oracle SQL to REDCap. REDCap offers a flexible way for developing customized study designs, even in the case of longitudinal studies with different study arms (ie, obstetric events, women, and mother-child pairs). However, REDCap does not offer built-in tools for preprocessing large data sets before data import. Additional software is needed (eg, R) for data formatting and cleaning to achieve the predefined REDCap data structure.
- 1 January 2023
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 7 (1) , e44567
Open AccessMigrating a Well-Established Longitudinal Cohort Database From Oracle SQL to Research Electronic Data Entry (REDCap): Data Management Research and Design Study
Background: Providing user-friendly electronic data collection tools for large multicenter studies is key for obtaining high-quality research data. Research Electronic Data Capture (REDCap) is a software solution developed for setting up research databases with integrated graphical user interfaces for electronic data entry. The Swiss Mother and Child HIV Cohort Study (MoCHiV) is a longitudinal cohort study with around 2 million data entries dating back to the early 1980s. Until 2022, data collection in MoCHiV was paper-based. Objective: The objective of this study was to provide a user-friendly graphical interface for electronic data entry for physicians and study nurses reporting MoCHiV data. Methods: MoCHiV collects information on obstetric events among women living with HIV and children born to mothers living with HIV. Until 2022, MoCHiV data were stored in an Oracle SQL relational database. In this project, R and REDCap were used to develop an electronic data entry platform for MoCHiV with migration of already collected data. Results: The key steps for providing an electronic data entry option for MoCHiV were (1) design, (2) data cleaning and formatting, (3) migration and compliance, and (4) add-on features. In the first step, the database structure was defined in REDCap, including the specification of primary and foreign keys, definition of study variables, and the hierarchy of questions (termed "branching logic"). In the second step, data stored in Oracle were cleaned and formatted to adhere to the defined database structure. Systematic data checks ensured compliance to all branching logic and levels of categorical variables. REDCap-specific variables and numbering of repeated events for enabling a relational data structure in REDCap were generated using R. In the third step, data were imported to REDCap and then systematically compared to the original data. In the last step, add-on features, such as data access groups, redirections, and summary reports, were integrated to facilitate data entry in the multicenter MoCHiV study. Conclusions: By combining different software tools-Oracle SQL, R, and REDCap-and building a systematic pipeline for data cleaning, formatting, and comparing, we were able to migrate a multicenter longitudinal cohort study from Oracle SQL to REDCap. REDCap offers a flexible way for developing customized study designs, even in the case of longitudinal studies with different study arms (ie, obstetric events, women, and mother-child pairs). However, REDCap does not offer built-in tools for preprocessing large data sets before data import. Additional software is needed (eg, R) for data formatting and cleaning to achieve the predefined REDCap data structure.
- Open Access
- 24 November 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Migrating a Well-Established Longitudinal Cohort Database From Oracle SQL to Research Electronic Data Entry (REDCap): Data Management Research and Design Study (Preprint)
BACKGROUND Providing user-friendly electronic data collection tools for large multicenter studies is key for obtaining high-quality research data. Research Electronic Data Capture (REDCap) is a software solution developed for setting up research databases with integrated graphical user interfaces for electronic data entry. The Swiss Mother and Child HIV Cohort Study (MoCHiV) is a longitudinal cohort study with around 2 million data entries dating back to the early 1980s. Until 2022, data collection in MoCHiV was paper-based. OBJECTIVE The objective of this study was to provide a user-friendly graphical interface for electronic data entry for physicians and study nurses reporting MoCHiV data. METHODS MoCHiV collects information on obstetric events among women living with HIV and children born to mothers living with HIV. Until 2022, MoCHiV data were stored in an Oracle SQL relational database. In this project, R and REDCap were used to develop an electronic data entry platform for MoCHiV with migration of already collected data. RESULTS The key steps for providing an electronic data entry option for MoCHiV were (1) design, (2) data cleaning and formatting, (3) migration and compliance, and (4) add-on features. In the first step, the database structure was defined in REDCap, including the specification of primary and foreign keys, definition of study variables, and the hierarchy of questions (termed “branching logic”). In the second step, data stored in Oracle were cleaned and formatted to adhere to the defined database structure. Systematic data checks ensured compliance to all branching logic and levels of categorical variables. REDCap-specific variables and numbering of repeated events for enabling a relational data structure in REDCap were generated using R. In the third step, data were imported to REDCap and then systematically compared to the original data. In the last step, add-on features, such as data access groups, redirections, and summary reports, were integrated to facilitate data entry in the multicenter MoCHiV study. CONCLUSIONS By combining different software tools—Oracle SQL, R, and REDCap—and building a systematic pipeline for data cleaning, formatting, and comparing, we were able to migrate a multicenter longitudinal cohort study from Oracle SQL to REDCap. REDCap offers a flexible way for developing customized study designs, even in the case of longitudinal studies with different study arms (ie, obstetric events, women, and mother-child pairs). However, REDCap does not offer built-in tools for preprocessing large data sets before data import. Additional software is needed (eg, R) for data formatting and cleaning to achieve the predefined REDCap data structure.
- 24 November 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessMigrating a Well-Established Longitudinal Cohort Database From Oracle SQL to Research Electronic Data Entry (REDCap): Data Management Research and Design Study (Preprint)
BACKGROUND Providing user-friendly electronic data collection tools for large multicenter studies is key for obtaining high-quality research data. Research Electronic Data Capture (REDCap) is a software solution developed for setting up research databases with integrated graphical user interfaces for electronic data entry. The Swiss Mother and Child HIV Cohort Study (MoCHiV) is a longitudinal cohort study with around 2 million data entries dating back to the early 1980s. Until 2022, data collection in MoCHiV was paper-based. OBJECTIVE The objective of this study was to provide a user-friendly graphical interface for electronic data entry for physicians and study nurses reporting MoCHiV data. METHODS MoCHiV collects information on obstetric events among women living with HIV and children born to mothers living with HIV. Until 2022, MoCHiV data were stored in an Oracle SQL relational database. In this project, R and REDCap were used to develop an electronic data entry platform for MoCHiV with migration of already collected data. RESULTS The key steps for providing an electronic data entry option for MoCHiV were (1) design, (2) data cleaning and formatting, (3) migration and compliance, and (4) add-on features. In the first step, the database structure was defined in REDCap, including the specification of primary and foreign keys, definition of study variables, and the hierarchy of questions (termed “branching logic”). In the second step, data stored in Oracle were cleaned and formatted to adhere to the defined database structure. Systematic data checks ensured compliance to all branching logic and levels of categorical variables. REDCap-specific variables and numbering of repeated events for enabling a relational data structure in REDCap were generated using R. In the third step, data were imported to REDCap and then systematically compared to the original data. In the last step, add-on features, such as data access groups, redirections, and summary reports, were integrated to facilitate data entry in the multicenter MoCHiV study. CONCLUSIONS By combining different software tools—Oracle SQL, R, and REDCap—and building a systematic pipeline for data cleaning, formatting, and comparing, we were able to migrate a multicenter longitudinal cohort study from Oracle SQL to REDCap. REDCap offers a flexible way for developing customized study designs, even in the case of longitudinal studies with different study arms (ie, obstetric events, women, and mother-child pairs). However, REDCap does not offer built-in tools for preprocessing large data sets before data import. Additional software is needed (eg, R) for data formatting and cleaning to achieve the predefined REDCap data structure.
- Open Access
- 27 October 2022
- Published by BMJ in BMJ Paediatrics Open
- Vol. 6 (1) , e001657
Paediatric COVID-19 mortality: a database analysis of the impact of health resource disparity
Background The impact of the COVID-19 pandemic on paediatric populations varied between high-income countries (HICs) versus low-income to middle-income countries (LMICs). We sought to investigate differences in paediatric clinical outcomes and identify factors contributing to disparity between countries. Methods The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) COVID-19 database was queried to include children under 19 years of age admitted to hospital from January 2020 to April 2021 with suspected or confirmed COVID-19 diagnosis. Univariate and multivariable analysis of contributing factors for mortality were assessed by country group (HICs vs LMICs) as defined by the World Bank criteria. Results A total of 12 860 children (3819 from 21 HICs and 9041 from 15 LMICs) participated in this study. Of these, 8961 were laboratory-confirmed and 3899 suspected COVID-19 cases. About 52% of LMICs children were black, and more than 40% were infants and adolescent. Overall in-hospital mortality rate (95% CI) was 3.3% [=(3.0% to 3.6%), higher in LMICs than HICs (4.0% (3.6% to 4.4%) and 1.7% (1.3% to 2.1%), respectively). There were significant differences between country income groups in intervention profile, with higher use of antibiotics, antivirals, corticosteroids, prone positioning, high flow nasal cannula, non-invasive and invasive mechanical ventilation in HICs. Out of the 439 mechanically ventilated children, mortality occurred in 106 (24.1%) subjects, which was higher in LMICs than HICs (89 (43.6%) vs 17 (7.2%) respectively). Pre-existing infectious comorbidities (tuberculosis and HIV) and some complications (bacterial pneumonia, acute respiratory distress syndrome and myocarditis) were significantly higher in LMICs compared with HICs. On multivariable analysis, LMIC as country income group was associated with increased risk of mortality (adjusted HR 4.73 (3.16 to 7.10)). Conclusion Mortality and morbidities were higher in LMICs than HICs, and it may be attributable to differences in patient demographics, complications and access to supportive and treatment modalities.
- 27 October 2022
- Published by BMJ in BMJ Paediatrics Open
- Vol. 6 (1) , e001657
Open AccessPaediatric COVID-19 mortality: a database analysis of the impact of health resource disparity
Background The impact of the COVID-19 pandemic on paediatric populations varied between high-income countries (HICs) versus low-income to middle-income countries (LMICs). We sought to investigate differences in paediatric clinical outcomes and identify factors contributing to disparity between countries. Methods The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) COVID-19 database was queried to include children under 19 years of age admitted to hospital from January 2020 to April 2021 with suspected or confirmed COVID-19 diagnosis. Univariate and multivariable analysis of contributing factors for mortality were assessed by country group (HICs vs LMICs) as defined by the World Bank criteria. Results A total of 12 860 children (3819 from 21 HICs and 9041 from 15 LMICs) participated in this study. Of these, 8961 were laboratory-confirmed and 3899 suspected COVID-19 cases. About 52% of LMICs children were black, and more than 40% were infants and adolescent. Overall in-hospital mortality rate (95% CI) was 3.3% [=(3.0% to 3.6%), higher in LMICs than HICs (4.0% (3.6% to 4.4%) and 1.7% (1.3% to 2.1%), respectively). There were significant differences between country income groups in intervention profile, with higher use of antibiotics, antivirals, corticosteroids, prone positioning, high flow nasal cannula, non-invasive and invasive mechanical ventilation in HICs. Out of the 439 mechanically ventilated children, mortality occurred in 106 (24.1%) subjects, which was higher in LMICs than HICs (89 (43.6%) vs 17 (7.2%) respectively). Pre-existing infectious comorbidities (tuberculosis and HIV) and some complications (bacterial pneumonia, acute respiratory distress syndrome and myocarditis) were significantly higher in LMICs compared with HICs. On multivariable analysis, LMIC as country income group was associated with increased risk of mortality (adjusted HR 4.73 (3.16 to 7.10)). Conclusion Mortality and morbidities were higher in LMICs than HICs, and it may be attributable to differences in patient demographics, complications and access to supportive and treatment modalities.
- Open Access
- 8 July 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (7) , e0270962
Simultaneous presence of Mycoplasma salivarium and Tannerella forsythia in the implant sulcus after lateral augmentation with autogenous root grafts is associated with increased sulcus probing depth
Objective: To characterize a potential pathogenic role of Mycoplasma salivarium and bacterial co-detection patterns on different implant augmentation types. Material and methods: 36 patients were non-randomly assigned to autogenous lateral alveolar ridge augmentation with either cortical autogenous bone blocks, or healthy autogenous tooth roots or non-preservable teeth. Mucosal inflammation was assessed by probing pocket depth (PD) at all sampling sites and by bleeding on probing (BOP) in a subset of sampling sites, and standardized biofilm samples were obtained from the submucosal peri-implant sulcus and sulcus of a contralateral tooth at two times (t1 after implant placement; t2 after six months). Seven bacterial species were quantified using Taqman PCR. Results: Mucosal inflammation did not differ between augmentation groups, but peri-implant sulci showed increased abundance of M. salivarium after augmentation with autogenous tooth roots lasting for at least six months (t1 p = 0.05, t2 p = 0.011). In M. salivarium-positive samples, Tannerella forsythia was correlated with PD (R = 0.25, p = 0.035) This correlation was not observed in M. salivarium-negative samples. Compared to all other samples, PD was deeper in co-detection (i.e., simultaneous M. salivarium and T. forsythia) positive samples (p = 0.022). No association of single or co-detection of bacteria with BOP was observed. Conclusion: Presence of M. salivarium in peri-implant sulci varies with augmentation method and is associated with increased PD but not BOP. A potential causal role of M. salivarium in inflammation through a mechanism involving co-presence of T. forsythia requires further study.
- 8 July 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (7) , e0270962
Open AccessSimultaneous presence of Mycoplasma salivarium and Tannerella forsythia in the implant sulcus after lateral augmentation with autogenous root grafts is associated with increased sulcus probing depth
Objective: To characterize a potential pathogenic role of Mycoplasma salivarium and bacterial co-detection patterns on different implant augmentation types. Material and methods: 36 patients were non-randomly assigned to autogenous lateral alveolar ridge augmentation with either cortical autogenous bone blocks, or healthy autogenous tooth roots or non-preservable teeth. Mucosal inflammation was assessed by probing pocket depth (PD) at all sampling sites and by bleeding on probing (BOP) in a subset of sampling sites, and standardized biofilm samples were obtained from the submucosal peri-implant sulcus and sulcus of a contralateral tooth at two times (t1 after implant placement; t2 after six months). Seven bacterial species were quantified using Taqman PCR. Results: Mucosal inflammation did not differ between augmentation groups, but peri-implant sulci showed increased abundance of M. salivarium after augmentation with autogenous tooth roots lasting for at least six months (t1 p = 0.05, t2 p = 0.011). In M. salivarium-positive samples, Tannerella forsythia was correlated with PD (R = 0.25, p = 0.035) This correlation was not observed in M. salivarium-negative samples. Compared to all other samples, PD was deeper in co-detection (i.e., simultaneous M. salivarium and T. forsythia) positive samples (p = 0.022). No association of single or co-detection of bacteria with BOP was observed. Conclusion: Presence of M. salivarium in peri-implant sulci varies with augmentation method and is associated with increased PD but not BOP. A potential causal role of M. salivarium in inflammation through a mechanism involving co-presence of T. forsythia requires further study.
- Open Access
- 26 April 2022
- Published by Springer Nature in BMC Pediatrics
- Vol. 22 (1) , 1-13
Infection control of COVID-19 in pediatric tertiary care hospitals: challenges and implications for future pandemics
More than 2 years into the COVID-19 pandemic, SARS-CoV-2 still impacts children’s health and the management of pediatric hospitals. However, it is unclear which hygiene and infection control measures are effective and useful for pediatric hospitals. Here, we report infection control measures implemented at a tertiary care children’s hospital. We evaluated frequency of SARS-CoV-2 detection in admitted patients, in-hospital transmission and infection related findings. Furthermore, we aimed to capture perspectives of health-care workers and caregivers on effectiveness and burden of infection control measures. Knowledge gained can inform management of the ongoing and future pandemics. We designed a retrospective observational study and survey at a pediatric tertiary care referral center. Local infection control measures and respective guidelines regarding COVID-19 were reviewed. Three thousand seven hundred sixteen children under 18 years were tested for SARS-CoV-2 at the University Children’s Hospital Tuebingen and data on SARS-CoV-2 transmission were retrieved from internal records. Two surveys were conducted among 219 staff members and 229 caregivers. Local infection control measures comprised the formation of a task force, triage, protective hygiene measures and an adaptable SARS-CoV-2 test strategy. Between January 2020 and March 2021, SARS-CoV-2 infection was detected in 37 children presenting to our hospital, 21 of these were admitted. One hospital-acquired infection occurred. About 90% of health-care staff perceived the majority of measures as effective and appropriate. However, visitor restrictions and cancellation of scheduled treatments were perceived least effective by hospital staff and as a particular burden for patients and their caregivers. Visits at the pediatric emergency department significantly decreased during the pandemic. We drafted a pandemic action plan by ranking infection control measures according to local transmission stages. SARS-CoV-2 infection control measures implemented in our tertiary care children’s hospital were evaluated by health-care workers as mostly effective and appropriate. In particular, good communication, transparency of decision-making as well as universal masking and infection screening were assessed as successful measures of infection control management. Visitor restrictions and cancellation of routine appointments, in contrast, were perceived as a particular burden on patient care and should be avoided. An established pandemic action plan may guide children’s hospitals in the future.
- 26 April 2022
- Published by Springer Nature in BMC Pediatrics
- Vol. 22 (1) , 1-13
Open AccessInfection control of COVID-19 in pediatric tertiary care hospitals: challenges and implications for future pandemics
More than 2 years into the COVID-19 pandemic, SARS-CoV-2 still impacts children’s health and the management of pediatric hospitals. However, it is unclear which hygiene and infection control measures are effective and useful for pediatric hospitals. Here, we report infection control measures implemented at a tertiary care children’s hospital. We evaluated frequency of SARS-CoV-2 detection in admitted patients, in-hospital transmission and infection related findings. Furthermore, we aimed to capture perspectives of health-care workers and caregivers on effectiveness and burden of infection control measures. Knowledge gained can inform management of the ongoing and future pandemics. We designed a retrospective observational study and survey at a pediatric tertiary care referral center. Local infection control measures and respective guidelines regarding COVID-19 were reviewed. Three thousand seven hundred sixteen children under 18 years were tested for SARS-CoV-2 at the University Children’s Hospital Tuebingen and data on SARS-CoV-2 transmission were retrieved from internal records. Two surveys were conducted among 219 staff members and 229 caregivers. Local infection control measures comprised the formation of a task force, triage, protective hygiene measures and an adaptable SARS-CoV-2 test strategy. Between January 2020 and March 2021, SARS-CoV-2 infection was detected in 37 children presenting to our hospital, 21 of these were admitted. One hospital-acquired infection occurred. About 90% of health-care staff perceived the majority of measures as effective and appropriate. However, visitor restrictions and cancellation of scheduled treatments were perceived least effective by hospital staff and as a particular burden for patients and their caregivers. Visits at the pediatric emergency department significantly decreased during the pandemic. We drafted a pandemic action plan by ranking infection control measures according to local transmission stages. SARS-CoV-2 infection control measures implemented in our tertiary care children’s hospital were evaluated by health-care workers as mostly effective and appropriate. In particular, good communication, transparency of decision-making as well as universal masking and infection screening were assessed as successful measures of infection control management. Visitor restrictions and cancellation of routine appointments, in contrast, were perceived as a particular burden on patient care and should be avoided. An established pandemic action plan may guide children’s hospitals in the future.
- Open Access
Profiling of humoral immune responses to norovirus in children across Europe
Human noroviruses are a major cause of gastroenteritis outbreaks worldwide. The majority of outbreaks and sporadic cases are caused by norovirus genotype GII.4 but 48 capsid genotypes and 60 polymerase genotypes (P-types) have been described, some of which are frequently reported while others are rarely detected. Little is known about the circulation and reservoirs of the less common genotypes. In this study, we have investigated whether children could pose a possible reservoir for undetected circulation of norovirus diversity. We, therefore, tested IgG and IgA responses of sera obtained from 287 children aged <1-month to 5.5-years on a protein microarray against P particles representing 30 norovirus GI and GII genotypes. We further profiled immune responses against the P-type by assessing antigenicity and seroprevalence of the non-structural proteins. The overall seroprevalence was 95.3% in children up to six months old (maternal antibodies), followed by a decrease to 59.6% up to 12 months, and an increase to 84.7% by the age of 5.5 years. We detected antibody responses against all tested genotypes, with the most specific IgG and IgA responses directed against the GII.2, GII.3, GII.4, and GII.6 capsid genotypes, which are the most frequently reported noroviruses in outbreaks. We also detected antibodies against the non-structural proteins p48 and p22 in sera of older children, predominantly against GII genotypes. While we found no evidence to suggest that rarely detected genotypes widely circulate in children, this is the first study to investigate seroprevalence against such a wide variety of human norovirus capsid and polymerase genotypes. Importance: Norovirus is a leading cause of epidemic acute gastroenteritis, causing severe disease in children, the elderly, and immunocompromised individuals. Although norovirus is a diverse genus of viruses, the majority of reported cases are caused by viruses of the GII.4 genotype. Many of the genotypes are rarely detected and it is unknown where they circulate between outbreaks. Here we investigated the possibility of children posing a reservoir for undetected circulation. While previous serological studies have tested antibodies against a limited set of capsid genotypes, we profiled the antibody repertoire of children against the capsid and the non-structural proteins, representing the known diversity of human noroviruses. While we detected high seroprevalence in children older than one year, we found no evidence to suggest a wide circulation of rare genotypes in children in Europe.
Open AccessProfiling of humoral immune responses to norovirus in children across Europe
Human noroviruses are a major cause of gastroenteritis outbreaks worldwide. The majority of outbreaks and sporadic cases are caused by norovirus genotype GII.4 but 48 capsid genotypes and 60 polymerase genotypes (P-types) have been described, some of which are frequently reported while others are rarely detected. Little is known about the circulation and reservoirs of the less common genotypes. In this study, we have investigated whether children could pose a possible reservoir for undetected circulation of norovirus diversity. We, therefore, tested IgG and IgA responses of sera obtained from 287 children aged <1-month to 5.5-years on a protein microarray against P particles representing 30 norovirus GI and GII genotypes. We further profiled immune responses against the P-type by assessing antigenicity and seroprevalence of the non-structural proteins. The overall seroprevalence was 95.3% in children up to six months old (maternal antibodies), followed by a decrease to 59.6% up to 12 months, and an increase to 84.7% by the age of 5.5 years. We detected antibody responses against all tested genotypes, with the most specific IgG and IgA responses directed against the GII.2, GII.3, GII.4, and GII.6 capsid genotypes, which are the most frequently reported noroviruses in outbreaks. We also detected antibodies against the non-structural proteins p48 and p22 in sera of older children, predominantly against GII genotypes. While we found no evidence to suggest that rarely detected genotypes widely circulate in children, this is the first study to investigate seroprevalence against such a wide variety of human norovirus capsid and polymerase genotypes. Importance: Norovirus is a leading cause of epidemic acute gastroenteritis, causing severe disease in children, the elderly, and immunocompromised individuals. Although norovirus is a diverse genus of viruses, the majority of reported cases are caused by viruses of the GII.4 genotype. Many of the genotypes are rarely detected and it is unknown where they circulate between outbreaks. Here we investigated the possibility of children posing a reservoir for undetected circulation. While previous serological studies have tested antibodies against a limited set of capsid genotypes, we profiled the antibody repertoire of children against the capsid and the non-structural proteins, representing the known diversity of human noroviruses. While we detected high seroprevalence in children older than one year, we found no evidence to suggest a wide circulation of rare genotypes in children in Europe.